Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab

Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncol Lett
Glavni autori: Nardone, Valerio, Tini, Paolo, Pastina, Pierpaolo, Botta, Cirino, Reginelli, Alfonso, Carbone, Salvatore Francesco, Giannicola, Rocco, Calabrese, Grazia, Tebala, Carmela, Guida, Cesare, Giudice, Aldo, Barbieri, Vito, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cappabianca, Salvatore, Capasso, Rosanna, Luce, Amalia, Caraglia, Michele, Mazzei, Maria Antonietta, Pirtoli, Luigi, Correale, Pierpaolo
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2020
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956423/
https://ncbi.nlm.nih.gov/pubmed/31966081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.11220
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items